Cargando…
Comment on Leelarathna et al. Duration of Hybrid Closed-Loop Insulin Therapy to Achieve Representative Glycemic Outcomes in Adults With Type 1 Diabetes. Diabetes Care 2020;43:e38–e39
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Diabetes Association
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510045/ https://www.ncbi.nlm.nih.gov/pubmed/32958628 http://dx.doi.org/10.2337/dc20-1291 |
| _version_ | 1783585709249003520 |
|---|---|
| author | Benhamou, Pierre Yves Madrolle, Stéphanie Lablanche, Sandrine Gallegos, Alexandre Tourki, Yousra Franc, Sylvia Doron, Maeva Charpentier, Guillaume |
| author_facet | Benhamou, Pierre Yves Madrolle, Stéphanie Lablanche, Sandrine Gallegos, Alexandre Tourki, Yousra Franc, Sylvia Doron, Maeva Charpentier, Guillaume |
| author_sort | Benhamou, Pierre Yves |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7510045 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | American Diabetes Association |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75100452020-10-02 Comment on Leelarathna et al. Duration of Hybrid Closed-Loop Insulin Therapy to Achieve Representative Glycemic Outcomes in Adults With Type 1 Diabetes. Diabetes Care 2020;43:e38–e39 Benhamou, Pierre Yves Madrolle, Stéphanie Lablanche, Sandrine Gallegos, Alexandre Tourki, Yousra Franc, Sylvia Doron, Maeva Charpentier, Guillaume Diabetes Care e-Letters: Comments and Responses American Diabetes Association 2020-10 2020-09-11 /pmc/articles/PMC7510045/ /pubmed/32958628 http://dx.doi.org/10.2337/dc20-1291 Text en © 2020 by the American Diabetes Association https://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license. |
| spellingShingle | e-Letters: Comments and Responses Benhamou, Pierre Yves Madrolle, Stéphanie Lablanche, Sandrine Gallegos, Alexandre Tourki, Yousra Franc, Sylvia Doron, Maeva Charpentier, Guillaume Comment on Leelarathna et al. Duration of Hybrid Closed-Loop Insulin Therapy to Achieve Representative Glycemic Outcomes in Adults With Type 1 Diabetes. Diabetes Care 2020;43:e38–e39 |
| title | Comment on Leelarathna et al. Duration of Hybrid Closed-Loop Insulin Therapy to Achieve Representative Glycemic Outcomes in Adults With Type 1 Diabetes. Diabetes Care 2020;43:e38–e39 |
| title_full | Comment on Leelarathna et al. Duration of Hybrid Closed-Loop Insulin Therapy to Achieve Representative Glycemic Outcomes in Adults With Type 1 Diabetes. Diabetes Care 2020;43:e38–e39 |
| title_fullStr | Comment on Leelarathna et al. Duration of Hybrid Closed-Loop Insulin Therapy to Achieve Representative Glycemic Outcomes in Adults With Type 1 Diabetes. Diabetes Care 2020;43:e38–e39 |
| title_full_unstemmed | Comment on Leelarathna et al. Duration of Hybrid Closed-Loop Insulin Therapy to Achieve Representative Glycemic Outcomes in Adults With Type 1 Diabetes. Diabetes Care 2020;43:e38–e39 |
| title_short | Comment on Leelarathna et al. Duration of Hybrid Closed-Loop Insulin Therapy to Achieve Representative Glycemic Outcomes in Adults With Type 1 Diabetes. Diabetes Care 2020;43:e38–e39 |
| title_sort | comment on leelarathna et al. duration of hybrid closed-loop insulin therapy to achieve representative glycemic outcomes in adults with type 1 diabetes. diabetes care 2020;43:e38–e39 |
| topic | e-Letters: Comments and Responses |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510045/ https://www.ncbi.nlm.nih.gov/pubmed/32958628 http://dx.doi.org/10.2337/dc20-1291 |
| work_keys_str_mv | AT benhamoupierreyves commentonleelarathnaetaldurationofhybridclosedloopinsulintherapytoachieverepresentativeglycemicoutcomesinadultswithtype1diabetesdiabetescare202043e38e39 AT madrollestephanie commentonleelarathnaetaldurationofhybridclosedloopinsulintherapytoachieverepresentativeglycemicoutcomesinadultswithtype1diabetesdiabetescare202043e38e39 AT lablanchesandrine commentonleelarathnaetaldurationofhybridclosedloopinsulintherapytoachieverepresentativeglycemicoutcomesinadultswithtype1diabetesdiabetescare202043e38e39 AT gallegosalexandre commentonleelarathnaetaldurationofhybridclosedloopinsulintherapytoachieverepresentativeglycemicoutcomesinadultswithtype1diabetesdiabetescare202043e38e39 AT tourkiyousra commentonleelarathnaetaldurationofhybridclosedloopinsulintherapytoachieverepresentativeglycemicoutcomesinadultswithtype1diabetesdiabetescare202043e38e39 AT francsylvia commentonleelarathnaetaldurationofhybridclosedloopinsulintherapytoachieverepresentativeglycemicoutcomesinadultswithtype1diabetesdiabetescare202043e38e39 AT doronmaeva commentonleelarathnaetaldurationofhybridclosedloopinsulintherapytoachieverepresentativeglycemicoutcomesinadultswithtype1diabetesdiabetescare202043e38e39 AT charpentierguillaume commentonleelarathnaetaldurationofhybridclosedloopinsulintherapytoachieverepresentativeglycemicoutcomesinadultswithtype1diabetesdiabetescare202043e38e39 |